Lipid H9
Formulation & Performance

This edition organizes the previously reviewed, source-linked product record. It is not a new independent review of every paper or supporting file. Reported and calculated values retain their original labels.

View original study figures ↓

Literature-reported H9 formulation

Component	mol%	Role
H9	50	Ionizable lipid
DOPE	10	Helper phospholipid
Cholesterol	38.5	Sterol
DMG-PEG2000	1.5	PEG lipid
Total	100	Top-performing H9 formulation in the Methods section

CargoFirefly luciferase mRNA (mFluc)

RouteIntramuscular injection

Dose0.5 mg/kg mFluc mRNA

ReadoutBioluminescence at 6 h

ModelMouse; n = 3 per group in Fig. 3f–h

N/P ratioNot reported for this comparison

Published mouse studyMuscle expression vs MC37.8×

Published mouse studyMuscle expression vs ALC-0315Comparable

Published mouse studyLiver and spleen expressionLower than benchmarks

In the mTmG reporter model, intramuscular H9 LNPs carrying Cre mRNA produced muscle GFP expression comparable to ALC-0315, with lower liver expression. In the separate mOVA prime-boost vaccination experiment, anti-OVA IgG was comparable to ALC-0315 and serum ALT/AST levels were lower (Supplementary Figs. S15 and S17).

Primary publicationXu Y, et al. AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery. Nature Communications 15, 6305 (2024). doi:10.1038/s41467-024-50619-z. H9 formulation: Methods, LNP formulation and characterization; IM results: Fig. 3e–j and Results.

Published study figures

Original publication figures illustrating the cited formulation and biological results. Select an image to view it at full size.

Figure 4: R6, H9 and benchmark LNPs are compared in RAW 264.7 and HeLa cells. Panels e–g show measured reporter expression, microscopy and flow cytometry; panels a–c show model predictions, not experimental efficacy. — Figure 4 — R6 and H9 show cell-dependent delivery
R6, H9 and benchmark LNPs are compared in RAW 264.7 and HeLa cells. Panels e–g show measured reporter expression, microscopy and flow cytometry; panels a–c show model predictions, not experimental efficacy. RAW 264.7 macrophages and HeLa cells; eGFP mRNA; n=6 for panel e and n=3 for microscopy; 20 µm scale bars.
Xu et al. (2024), Nature Communications, Figure 4. CC BY 4.0. Original figure unchanged. Original article / figure · CC BY 4.0. Unmodified complete original figure; displayed at responsive size.

Lipid H9Formulation & Performance

Literature-reported H9 formulation

Published study figures

Figure 4 — R6 and H9 show cell-dependent delivery

Lipid H9
Formulation & Performance